177Lu-octreotate

You have access
Analysis of ¹⁷⁷Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin and Rodney J. Hicks

Journal of Nuclear Medicine April 1, 2015, 56 (4) 505-511; DOI: https://doi.org/10.2967/jnumed.114.145581
You have access
Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate
Samer Ezziddin, Mared Attassi, Charlotte J. Yong-Hing, Hojjat Ahmadzadehfar, Winfried Willinek, Frank Grünwald, Stefan Guhlke, Hans-Jürgen Biersack and Amir Sabet

Journal of Nuclear Medicine February 1, 2014, 55 (2) 183-190; DOI: https://doi.org/10.2967/jnumed.113.125336
You have access
Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate
Amir Sabet, Khaled Ezziddin, Ulrich-Frank Pape, Hojjat Ahmadzadehfar, Karin Mayer, Thorsten Pöppel, Stefan Guhlke, Hans-Jürgen Biersack and Samer Ezziddin

Journal of Nuclear Medicine November 1, 2013, 54 (11) 1857-1861; DOI: https://doi.org/10.2967/jnumed.112.119347

Main menu